去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析

覃艳新; 龙富立; 毛德文; 张建玲; 马玉珍; 闫连杰

doi:10.3969/j.issn.1001-5256.2019.10.027

去甲肾上腺素或特利加压素联合白蛋白治疗1型肝肾综合征效果及安全性比较的Meta分析

DOI: 10.3969/j.issn.1001-5256.2019.10.027

1. 广西中医药大学
2. 广西中医药大学第一附属医院

基金项目:

国家自然科学基金(81774236,81760844,81503520,81560752)；广西科技计划项目(桂科AD17129001,桂科攻1598011-7,桂科AA17202036)；广西中医药大学校级一般硕士研究生创新项目(YCSY2018026)；广西高等学校高水平创新团队及卓越学者项目；国家中医药管理局“慢性重型肝炎解毒化瘀”重点研究室；

详细信息

中图分类号: R575;R692
计量
- 文章访问数: 1286
- HTML全文浏览量: 65
- PDF下载量: 238
- 被引次数: 0
出版历程
- 收稿日期: 2019-06-06
- 出版日期: 2019-10-20

Efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in treatment of type 1 hepatorenal syndrome:A Meta-analysis

Guangxi University of Chinese Medicine

Research funding:

摘要

摘要:
目的对去甲肾上腺素、特利加压素联合白蛋白治疗1型肝肾综合征（HRS1）的效果及安全性进行系统评价。方法通过检索PubMed、EMBASE、Medline、Cochrane Library、中国知网、万方和维普等国内外数据库有关去甲肾上腺素或特利加压素联合白蛋白治疗HRS1对比研究的文献。对文献进行质量评价。提取HRS逆转率、病死率、不良事件发生率、平均动脉压、肾功能等指标,应用Review Manager 5. 3软件进行数据分析,各研究间的异质性采用χ2检验判断。二分类变量采用比值比（OR）分析,连续性变量采用加权均数差（WMD）分析,两类变量均计算95%可信区间（95%CI）。结果纳入符合标准的随机对照试验6篇,总样本量298例,其中去甲肾上腺素联合白蛋白和特利加压素联合白蛋白组各149例。Meta分析显示两组的HRS逆转率（OR=0. 95,95%CI:0. 60～1. 49,P=0. 81）、病死率（OR=0. 84,95%CI:0. 51～1. 41,P=0. 51）、不良事件发生率（OR=0. 42,95%CI:0. 16～1. 07,P=0. 07）、平均动脉压（SMD=...
- 肝肾综合征 /
- 去甲肾上腺素 /
- 特利加压素 /
- 血清白蛋白 /
- Meta分析(主题)
Abstract:
Objective To systematically review the efficacy and safety of norepinephrine combined with albumin versus terlipressin combined with albumin in the treatment of type 1 hepatorenal syndrome(HRS1). Methods Pub Med,EMBASE,Medline,Cochrane Library,CNKI,Wanfang Data,and VIP were searched for comparative studies on norepinephrine combined with albumin versus terlipressin combined with albumin in the treatment of HRS1. Quality assessment was performed for articles. Related indicators were extracted,including hepatorenal syndrome(HRS) reversal rate,mortality rate,incidence of adverse events,mean arterial pressure,and renal function,and Review Manager 5. 3 was used for data analysis. The chi-square test was used to determine the heterogeneity between studies. Odds ratio(OR) was used for the analysis of dichotomous variables,weighted mean difference(WMD) was used for the analysis of continuous variables,and 95% confidence interval(CI) was calculated for these two types of variables. Results A total of 6 randomized controlled trials which met the inclusion criteria were included,with a total sample size of 298 patients(149 patients in the norepinephrine + albumin group and 149 in the terlipressin + albumin group). The meta-analysis showed that there were no significant differences between the two groups in HRS reversal rate(OR = 0. 95,95% CI: 0. 6-1. 49,P = 0. 81),mortality rate(OR = 0. 84,95% CI: 0. 51-1. 41,P = 0. 51),incidence rate of adverse events(OR =0. 42,95% CI: 0. 16-1. 07,P = 0. 07),mean arterial pressure(standardized mean difference = 0. 05,95% CI:-0. 92 to 1. 03,P = 0. 92),and renal function. Conclusion Norepinephrine combined with albumin has similar efficacy and safety as terlipressin combined with albumin in the treatment of HRS1,and terlipressin can be replaced by norepinephrine in clinical practice when necessary.
- hepatorenal syndrome /
- norepinephrine /
- terlipressin /
- serum albumin /
- Meta-analysis as topic

HTML全文

参考文献(30)

[1] FUKUI H,SAITO H,UENO Y,et al. Evidence-based clinical practice guidelines for liver cirrhosis 2015[J]. J Gastroenterol,2016,51(7):629-650.

[2] SALERNO F,CAZZANIGA M,MERLI M,et al. Diagnosis,treatment and survival of patients with hepatorenal syndrome:A survey on daily medical practice[J]. J Hepatol,2011,55(6):1241-1248.

[3] HEIDEMANN J,BARTELS C,BERSSENBRGGE C,et al.Hepatorenal syndrome:Outcome of response to therapy and predictors of survival[J]. Gastroenterol Res Pract,2015,45(7):6-13.

[4] KURT L,ROBERT B,LISBETH K,et al. Treatment and management of ascites and hepatorenal syndrome:An update[J]. Therap Adv Gastroenterol,2015,8(2):83-100.

[5] GIN SA,ESCORSELL A,GIN SP,et al. Incidence,predictive factors,and prognosis of the hepatorenal syndrome in cirrhosis with ascites[J]. Gastroenterology,1993,105(1):229-236.

[6] GIN SP,GUEVARA M,ARROYO V,et al. Hepatorenal syndrome[J]. Lancet,2003,36(2):1819-1827.

[7] BOYER TD,SANYAL AJ,GARCIA-TSAO G,et al. Impact of liver transplantation on the survival of patients treated for hepatorenal syndrome type 1[J]. Liver Transpl,2011,17(11):1328-1332.

[8] UTAKO P,EMYOO T,ANOTHAISINTAWEE T,et al. Clinical outcomes after liver transplantation for hepatorenal syndrome:A systematic review and meta-analysis[J]. Biomed Res Int,2018,2018(5):s1123.

[9] GLUUD LL,KURT C,ERIK C,et al. Systematic review of randomized trials on vasoconstrictor drugs for hepatorenal syndrome[J]. Hepatology,2010,51(2):576-584.

[10] SUN MY,TANG SH,ZENG WZ,et al. An excerpt of 2017KASL clinical practice guidelines for liver cirrhosis:Ascites and related complications[J]. J Clin Hepatol,2018,34(9):1877-1878.(in Chinese)孙梦滢,汤善宏,曾维政.《2017年韩国肝病学会临床实践指南:肝硬化-腹水及相关并发症》摘译[J].临床肝胆病杂志,2018,34(9):1877-1878.

[11] SANYAL AJ,BOYER T,GARCIA-TSAO G,et al. A randomized,prospective,double-blind,placebo-controlled trial of terlipressin for type 1 hepatorenal syndrome[J]. Gastroenterology,2008,134(5):1360-1368.

[12] FRANCESCO S,ALEXANDER G,PERE G,et al. Diagnosis,prevention and treatment of hepatorenal syndrome in cirrhosis[J]. Gut,2007,84(998):1310-1318.

[13] PAOLO A,PERE G,FLORENCE W,et al. Diagnosis and management of acute kidney injury in patients with cirrhosis:Revised consensus recommendations of the International Club of Ascites[J]. J Hepatol,2015,62(4):968-974.

[14] ARROYO V,GINES P,GERBES AL,et al. Definition and diagnostic criteria of refractory ascites and hepatorenal syndrome in cirrhosis[J]. Hepatology,1996,23(1):164-176.

[15] SHARMA P,KUMAR A,SHRAMA BC,et al. An open label,pilot,randomized controlled trial of noradrenaline versus terlipressin in the treatment of type 1 hepatorenal syndrome and predictors of response[J]. Am J Gastroenterol,2008,103(103):1689-1697.

[16] SINGH V,GHOSH S,SINGH B,et al. Noradrenaline vs. terlipressin in the treatment of hepatorenal syndrome:A randomized study[J]. J Hepatol,2012,56(6):1293-1298.

[17] GOYAL O,SIDHU SS,SEHGAL N,et al. Noradrenaline is as effective as terlipressin in hepatorenal syndrome type 1:A prospective,randomized trial[J]. J Assoc Physicians India,2016,64(9):30-35.

[18] SAIF RU,DAR HA,SOFI SM,et al. Noradrenaline versus terlipressin in the management of type 1 hepatorenal syndrome:A randomized controlled study[J]. Indian J Gastroenterol,2018,37(5):424-429.

[19] INDRABI RA,JAVID G,ZARGAR SA,et al. Noradrenaline is equally effective as terlipressin in reversal of type 1 hepatorenal syndrome:A randomized prospective study[J]. J Clin Exp Hepatol,2013,3(1):s97.

[20] BADAWY S,MECKAWY N,AHMED A. Norepinephrine versus terlipressin in patients with type 1 hepatorenal syndrome refractory to treatment with octreotide,midodrine,and albumin(a prospective randomized comparative study)[J]. Egyptian J Cardiothorac Anesth,2013,7(1):13-18.

[21] VICENTE A,JAVIER F. Management of hepatorenal syndrome in patients with cirrhosis[J]. Nat Rev Nephrol,2011,7(9):517-526.

[22] BRIGLIA AE,ANANIA FA. Hepatorenal syndrome. Definition,pathophysiology,and intervention[J]. Crit Care Clin,2002,18(2):345-373.

[23] LAURENCE L,SIBA K,ISABELLE CD,et al. Impact of molecular adsorbent recirculating system on renal recovery in type-1 hepatorenal syndrome patients with chronic liver failure[J].J Gastroenterol Hepatol,2013,28(6):1019-1024.

[24] CORT JH,ALBRECHT I,NOVAKOVA J,et al. Rregional and systemic haemodynamic effect of somevasopressins:Structural features of the hormone which prolong activity[J]. Eur J Clin Invest,1975,5(2):165-175.

[25] PAPALUCA T,GOW P. Terlipressin:Current and emerging indications in chronic liver disease[J]. Gastroenterol Hepatol,2018,33(3):591-598.

[26] KURT L. Noradrenaline in the treatment of patients with hepatorenal syndrome-back to the roots?[J]. J Hepatol,2012,57(4):925-926.

[27] SRIDHARAN K,SIVARAMAKRISHNAN G. Vasoactive agents for hepatorenal syndrome:A mixed treatment comparison network meta-analysis and trial sequential analysis of randomized clinical trials[J]. J Gen Intern Med,2017,33(1):97-102.

[28] NANDA A,REDDY R,SAFRAZ H,et al. Pharmacological therapies for hepatorenal syndrome:A systematic review and meta-analysis[J]. J Clin Gastroenterol,2018,52(4):360-367.

[29] NASSAR JUNIOR AP,FARIAS AQ,D'ALBUQUERQUE LA,et al. Terlipressin versus norepinephrine in the treatment of hepatorenal syndrome:A systematic review and meta-analysis[J]. PLo S ONE,2014,9(9):e107466.

[30] LIU QY,LI H. Changes in diagnostic criteria for hepatorenal syndrome and the application of new renal injury indices in cirrhotic patients[J]. J Clin Hepatol,2018,34(6):1308-1312.(in Chinese)刘沁雨,李海.肝肾综合征临床诊断标准的变迁及新的肾损伤指标在肝硬化患者中的应用[J].临床肝胆病杂志,2018,34(6):1308-1312.

施引文献

资源附件(0)

访问统计